In 967 healthy adults aged ≥50, giving the recombinant shingles vaccine (RZV) with an mRNA COVID-19 or adjuvanted influenza vaccine was non-inferior for antibody responses to all vaccines; severe systemic reactions were low but slightly higher with co-administration (max 3.3%).
RCTn = 967
Harris et al. Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial